Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Andrea Centritto
Observed names:
A Centritto,
A. Centritto
Institutions:
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”,
Guy's Hospital,
St Thomas' Hospital,
Guy's and St Thomas' NHS Foundation Trust
Observed institutions:
University of Messina,
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”,
Guy's Hospital,
St Thomas' Hospital,
Guy's and St Thomas' NHS Foundation Trust,
Azienda Ospedaliera Universitaria Policlinico "G. Martino",
University of Bologna
show all 7
ORCID:
0009-0007-6682-2700
Observed ORCID:
0009-0007-6682-2700
OpenAlex ID:
A5034891419
The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches
2020
·
Fabio Salvatore Macaluso
, Walter Fries
, et al.
·
Inflammatory Bowel Diseases
·
52
Clinical Utility and Cost‐Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine‐Induced Myelosuppression: A Genotype‐First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource
2025
·
Christopher Roberts
, Jaime Peters
, et al.
·
Alimentary Pharmacology & Therapeutics
·
12
PDF
Higher Adalimumab Concentration Is Associated With Complete Fistula Healing in Patients With Perianal Fistulizing Crohn’s Disease
2024
·
Konstantinos Papamichael
, Andrea Centritto
, et al.
·
Clinical Gastroenterology and Hepatology
·
12
PDF
Letter: SPOSIB SB2—a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2
2018
·
Fabio Salvatore Macaluso
, Maria Cappello
, et al.
·
Alimentary Pharmacology & Therapeutics
·
9
PDF
P999 First in human treatment of Crohn’s disease with autologous ex-vivo expanded polyclonal, gut-targeted regulatory T cells: Initial results of the TRIBUTE feasibility study
2024
·
P M Irving
, D Seah
, et al.
·
Journal of Crohn s and Colitis
·
5
PDF
P1072 Upadacitinib appears effective in inducing clinical, biochemical, endoscopic and histologic improvements in previously treatment refractory Ulcerative Colitis
2024
·
X Y Choon
, C Patel
, et al.
·
Journal of Crohn s and Colitis
·
3
PDF
Isolated perianal fistulizing Crohn’s disease in contemporary clinical practice: a multicenter ECCO-CONFER cohort study
2026
·
Kumarini Basnayake
, Deloshaan Subhaharan
, et al.
·
Journal of Crohn s and Colitis
·
2
Anti-tumor Necrosis Factor Drug Concentration Is Not Associated with Disease Outcomes in Pouchitis: A Retrospective, International Study
2025
·
Sailish Honap
, Bénédicte Caron
, et al.
·
Digestive Diseases and Sciences
·
2
P1064 Association of subcutaneous infliximab CT-P13 serum levels and therapeutic outcomes in patients affected by Inflammatory Bowel Disease: A retrospective international multicentric study
2025
·
A Centritto
, M Samaan
, et al.
·
Journal of Crohn s and Colitis
·
2
PDF
P425 SPOSIB SB2: a Sicilian prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar SB2
2020
·
F S Macaluso
, W Fries
, et al.
·
Journal of Crohn s and Colitis
·
2
982 Randomised Controlled Trial of Withdrawal of Thiopurines When Switching From Intravenous to Subcutaneous Infliximab: Results of the Minimise Study
2026
·
Peter M. Irving
, Andrea Centritto
, et al.
·
Gastroenterology
·
1
DOP108 Randomised controlled trial of withdrawal of thiopurines in patients with IBD switching from intravenous to subcutaneous infliximab: Results of the MINIMISE study
2026
·
P M Irving
, A Centritto
, et al.
·
Journal of Crohn s and Colitis
·
1
PDF
P0150 A precision medicine approach for carriers of defined IL2RA polymorphism: JAK inhibition blocks exaggerated IL-2 signalling in vitro, with no difference in in vivo clinical response rates in a small clinical cohort
2025
·
J Clough
, S Honap
, et al.
·
Journal of Crohn s and Colitis
·
1
Can baseline infliximab clearance help guide the need for dose intensification in acute severe ulcerative colitis, or are we still dosing in the dark?
2026
·
Andrea Centritto
, Krisztina B Gecse
, et al.
·
Frontline Gastroenterology
O62 Randomised controlled trial of withdrawal of thiopurines when switching from intravenous to subcutaneous infliximab: results of the MINIMISE study
2026
·
Peter Irving
, Andrea Centritto
, et al.
·
Gut
PDF
P245 Old story, new angle. In-situ demonstration of mycobacterium paratuberculosis in lamina propria immune cells using IS900 FISH in crohn’s disease
2026
·
Marcus Barr
, Neil Rayment
, et al.
·
Gut
1058a EARLY INTESTINAL ULTRASOUND AND FECAL CALPROTECTIN PREDICT ENDOSCOPIC RECURRENCE AFTER ILEOCECAL RESECTION IN CROHN’S DISEASE: THE INSIGHT STUDY
2026
·
Maarten Pruijt
, Reimer Janssen
, et al.
·
Gastroenterology
982 Randomised Controlled Trial of Withdrawal of Thiopurines When Switching From Intravenous to Subcutaneous Infliximab: Results of the Minimise Study
2026
·
Peter M. Irving
, Andrea Centritto
, et al.
·
Gastrointestinal Endoscopy
1058a EARLY INTESTINAL ULTRASOUND AND FECAL CALPROTECTIN PREDICT ENDOSCOPIC RECURRENCE AFTER ILEOCECAL RESECTION IN CROHN’S DISEASE: THE INSIGHT STUDY
2026
·
Maarten Pruijt
, Reimer Janssen
, et al.
·
Gastrointestinal Endoscopy
Tu1880: ASSOCIATION OF SUBCUTANEOUS INFLIXIMAB CT-P13 SERUM CONCENTRATIONS AND THERAPEUTIC OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE INTERNATIONAL MULTICENTRE STUDY
2025
·
Andrea Centritto
, An Outtier
, et al.
·
Gastroenterology
Tu1822: NEW ONSET ACNE REPORTED IN THE MAJORITY OF PATIENTS WITH UPADACITINIB-TREATED INFLAMMATORY BOWEL DISEASE
2025
·
Fatima Omrani
, Esha Sharma
, et al.
·
Gastroenterology
Su1882: RELAPSE OF ULCERATIVE COLITIS ON DOSE REDUCTION OF TOFACITINIB IS ASSOCIATED WITH MARKERS OF T CELL ACTIVATION BUT NOT CLINICAL FEATURES: A PROSPECTIVE, MULTICENTRE OBSERVATIONAL STUDY
2025
·
Sailish Honap
, Sangmi Kim
, et al.
·
Gastroenterology
P0169 Relapse of ulcerative colitis on dose reduction of tofacitinib is associated with markers of T-cell activation but not clinical features: a prospective, multicentre observational study
2025
·
S Honap
, S Kim
, et al.
·
Journal of Crohn s and Colitis
PDF
Su1803 HIGHER MAINTENANCE ADALIMUMAB CONCENTRATION IS ASSOCIATED WITH COMPLETE FISTULA HEALING IN PATIENTS WITH PERIANAL FISTULIZING CROHN'S DISEASE
2024
·
Konstantinos Papamichail
, Andrea Centritto
, et al.
·
Gastroenterology
T04.01.19 Ustekinumab in Crohn's Disease: Real-world Outcomes From the Sicilian Network for Inflammatory Bowel Diseases (sn-ibd) – Preliminary Results
2020
·
A. Centritto
, G. Fiocco
, et al.
·
Digestive and Liver Disease
Show more works
View as search
Works count:
32
Citation count:
104
H-index:
5
I10-index:
3
Year
Topic
Type